Actinogen Medical

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

Equities

Equities by Sector

Sectors

Thematics

Latest

UK equities: A generational opportunity?

Renewable energy developers – Creating value for investors

Healthcare-focused trusts: A sector on the mend

Audiovisual

Latest

Oryzon Genomics – executive interview

Basilea Pharmaceutica – executive interview

Webinar – AI for IR: About our coaching programme

About Edison

About Edison

Careers

Actinogen Medical (ASX: ACW)

Latest Insights

Actinogen Medical — A$11.1m capital raise completed

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Actinogen Medical — Further positive XanaCIDD results on depression

Actinogen Medical — XanaCIDD data narrow the focus in depression

Sector

Equity Analyst

Key Management

Actinogen Medical — Funding the next stage of Xanamem development

Actinogen Medical — Refining the upcoming XanaMIA Phase IIb study

Actinogen Medical — Continued focus on Xanamem

Actinogen Medical — Getting ready for the next Alzheimer’s study

Actinogen Medical — On track to start Phase IIb XanaMIA study

Actinogen Medical — XanaMIA clears hurdle to start US recruitment

Actinogen Medical — XanaCIDD study in MDD now underway

Actinogen Medical – executive interview

Actinogen Medical — Cognitive enhancer targeting key diseases

Actinogen Medical — Cognitive enhancer targeting key diseases

Actinogen Medical — Cognitive enhancer targeting key diseases

Actinogen: Edison Open House Healthcare 2022

Executive interview – Actinogen Medical

Actinogen Medical — Well-timed XanaHES study saves the day

Actinogen Medical — Phase II XanADu trial results

Executive interview – Actinogen Medical

Actinogen Medical — Differentiated treatment for Alzheimer’s disease